Oncology

Your Article Summary

See Latest Articles

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study
The Lancet Oncology - Online First, 09/03/09

Agnelli G et al. – Nadroparin reduces the incidence of thromboembolic events in ambulatory patients with metastatic or locally advanced cancer who are receiving chemotherapy.

• 1150 ambulatory patients with lung, gastrointestinal, pancreatic, breast, ovarian, or head and neck cancer were randomly assigned in a double-blind manner to receive sc injections of nadroparin (3800 IU anti-Xa once a day, n=779) or placebo (n=387)
• Tx was given for the duration of chemotherapy up to a maximum of 4 months
• 769 patients were in the nadroparin group and 381 patients in the placebo group

• 15 (2·0%) of 769 patients treated with nadroparin and 15 (3·9%) of 381 patients treated with placebo had a thromboembolic events
• Five (0·7%) of 769 patients in the nadroparin group and no patients in the placebo group had a major bleeding event
• The incidences of minor bleeding were 7·4% (57 of 769) with nadroparin and 7·9% (30 of 381) with placebo
• There were 121 (15·7%) serious adverse events in the nadroparin goup and 67 (17·6%) serious adverse events in the placebo group

Today in Breast...keeping you current

Receive free subspecialty "5-minute updates" via email

Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement
Annals of Internal Medicine, 11/17/09

Activity of fulvestrant in HER2-overexpressing advanced breast cancer
Annals of Oncology, 11/06/09

The association of metabolic syndrome with triple-negative breast cancer
Breast Cancer Research and Treatment, 10/28/09

See All of Breast

Today in GI Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer
Journal of Clinical Oncology, 10/29/09

Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer
Journal of Clinical Oncology, 11/03/09

See All of GI Oncology

Today in Gynecologic Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Ovarian cancer screening and early detection
Women's Health, 11/04/09

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia
New England Journal of Medicine, 11/06/09

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
British Journal of Cancer, 11/02/09

See All of Gynecologic Oncology

Today in Head and Neck...keeping you current

Receive free subspecialty "5-minute updates" via email

Mobile Phone Use and Risk of Tumors: A Meta-Analysis
Journal of Clinical Oncology, 10/20/09

Thyroid lymphoma and airway obstruction – is there a rationale for surgical management?
International Journal of Clinical Practice, 10/19/09

Primary extranodal marginal zone lymphoma of the uvea associated with massive diffuse epibulbar extension and focal infiltration of the optic nerve and meninges, clinically presented as uveitis masquerade syndrome: a case report
Medical Oncology, 10/16/09

See All of Head and Neck

Today in Hepatobiliary/Pancreas...keeping you current

Receive free subspecialty "5-minute updates" via email

Macronutrients, fatty acids, cholesterol and pancreatic cancer
European Journal of Cancer, 10/27/09

Surgical management of hepatocellular carcinoma: Is the jury still out
Surgical Oncology, 11/05/09

Novel agents for the treatment of adenocarcinoma of the pancreas
Expert Review of Anticancer Therapy, 10/22/09

See All of Hepatobiliary/Pancreas

Today in Lung/Thoracic Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase III study
The Lancet, 10/26/09

Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer
Journal of Clinical Oncology, 10/29/09

New Advances in the Second-Line Treatment of Small Cell Lung Cancer
The Oncologist, 10/28/09

See All of Lung/Thoracic Oncology